GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting
Details of the ASCO presentations include:
Abstract #2520
Poster discussion. DeAngelo, D.J., et al. "GMI-1271, a Novel E-Selectin
Antagonist, in Combination with Chemotherapy in Relapsed/Refractory
AML." Session Title: Poster Discussion Session: Developmental
Therapeutics—Clinical Pharmacology and Experimental Therapeutics,
Presenter:
Abstract #2560
Poster. DeAngelo, D.J. et al. "GMI-1271, a Novel E-Selectin Antagonist,
Combined with Induction Chemotherapy in Elderly Patients with Untreated
AML." Session Title: Poster Session: Developmental Therapeutics—Clinical
Pharmacology and Experimental Therapeutics.
Presenter:
The ASCO Annual Meeting 2017 takes place from
About
GlycoMimetics is a clinical-stage biotechnology company focused on
cancer and sickle cell disease.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1271. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170420005978/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media